Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANG Lifesciences IndiaBOM:540694 -3.92%60 PS Ratio is 0.48 as of Aug. 05, 2026, which is 8% below its 10-year median of 0.52. GuruFocus rates BOM:540694 with a GF Score™ of 60/100 and a GF Value™ of ₹30.29 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 954 Drug Manufacturers companies, ANG Lifesciences India ranks better than 87.74% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ANG Lifesciences India's share price is ₹34.30.
ANG Lifesciences India's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹70.94. Hence, ANG Lifesciences India's PS Ratio for today is 0.48.
The historical rank and industry rank for ANG Lifesciences India's PS Ratio or its related term are showing as below:
BOM:540694'
s PS Ratio Range Over the Past 10 Years
Min: 0.26 Med: 0.52 Max: 2.51
Current: 0.5
During the past 13 years, ANG Lifesciences India's highest PS Ratio was 2.51. The lowest was 0.26. And the median was 0.52.
BOM:540694's PS Ratio is ranked better than 87.74% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.31
vs BOM:540694: 0.50
ANG Lifesciences India Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of ANG Lifesciences India was 0.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -25.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -19.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.70% per year.
During the past 13 years, ANG Lifesciences India's highest 3-Year average Revenue per Share Growth Rate was 53.80% per year. The lowest was -40.70% per year. And the median was 25.20% per year.
ANG Lifesciences India (BOM:540694) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ANG Lifesciences India's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANG Lifesciences India PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANG Lifesciences India's PS Ratio distribution charts can be found below:
* The bar in red indicates where ANG Lifesciences India's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
ANG Lifesciences India's Share Price of today is ₹34.30. ANG Lifesciences India's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹70.94.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ANG Lifesciences India (BOM:540694) has a PS Ratio of 0.48 as of Aug. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ANG Lifesciences India and its competitors. This is near median its historical median of 0.52. Over the past decade, ANG Lifesciences India's PS Ratio has ranged from 0.26 to 2.51. According to the industry distribution chart, ANG Lifesciences India ranks #117 out of 954 companies in the Drug Manufacturers industry, placing it in the top 12.3%.
Is ANG Lifesciences India's PS Ratio too high?
ANG Lifesciences India's current PS Ratio of 0.48 is near median its 10-year median of 0.52. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 2.51. The Drug Manufacturers industry median PS Ratio is 2.31. ANG Lifesciences India's value of 0.48 is 79.2% below this industry median. Based on the distribution chart, ANG Lifesciences India ranks #117 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ANG Lifesciences India has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ANG Lifesciences India's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, ANG Lifesciences India ranks #117 out of 954 companies for PS Ratio. This places ANG Lifesciences India in the top 12% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.31. ANG Lifesciences India's value of 0.48 is 79.2% below this benchmark. Historically, ANG Lifesciences India's own PS Ratio has ranged from 0.26 to 2.51 over the past decade. While the company's 10-year median is 0.52 vs. the industry median of 2.31, ANG Lifesciences India has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.31, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANG Lifesciences India's current PS Ratio of 0.48 is 79.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ANG Lifesciences India and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANG Lifesciences India's current PS Ratio is 0.48, which is near median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANG Lifesciences India stock overvalued right now?
Based on GuruFocus' analysis, ANG Lifesciences India (BOM:540694) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹30.29, compared to a current price of ₹34.30 — trading 13.2% above its estimated fair value. The current PS Ratio is 0.48, which is near median its 10-year median of 0.52 and 79.2% below the Drug Manufacturers industry median of 2.31. ANG Lifesciences India's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For ANG Lifesciences India (BOM:540694), the current PS Ratio is 0.48 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?
Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be overvalued.
The current stock price of ₹34.30 is trading 13.2% above its estimated GF Value™ of ₹30.29.
GuruFocus considers ANG Lifesciences India to be Modestly Overvalued.
Key valuation signals for BOM:540694:
PS Ratio: 0.48 (near median its 10-year median of 0.52)
GF Value™: ₹30.29 vs. price of ₹34.30 (13.2% above fair value)
Industry Position: 79.2% below the Drug Manufacturers median (#117 of 954)
No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
60GF Score
Get the complete analysis for BOM:540694
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540694 has been successfully added to your 
